{"owner": "ArrayExpress Uploader", "pop_total": 0, "id": 6952, "factors": [{"GSM967852": {"TREATED WITH": "phosphate buffered saline (PBS) as a control"}}, {"GSM967852": {"TREATED WITH": "phosphate buffered saline (PBS) as a control"}}, {"GSM967852": {"TREATED WITH": "phosphate buffered saline (PBS) as a control"}}, {"GSM967852": {"TREATED WITH": "phosphate buffered saline (PBS) as a control"}}, {"GSM967852": {"TREATED WITH": "phosphate buffered saline (PBS) as a control"}}, {"GSM967857": {"TREATED WITH": "dibenzazepine (DBZ) (8.1mmol/kg)"}}, {"GSM967857": {"TREATED WITH": "dibenzazepine (DBZ) (8.1mmol/kg)"}}, {"GSM967857": {"TREATED WITH": "dibenzazepine (DBZ) (8.1mmol/kg)"}}, {"GSM967857": {"TREATED WITH": "dibenzazepine (DBZ) (8.1mmol/kg)"}}, {"GSM967857": {"TREATED WITH": "dibenzazepine (DBZ) (8.1mmol/kg)"}}, {"GSM967862": {"TREATED WITH": "Bevacizumab (10mg/kg body weight)"}}, {"GSM967862": {"TREATED WITH": "Bevacizumab (10mg/kg body weight)"}}, {"GSM967862": {"TREATED WITH": "Bevacizumab (10mg/kg body weight)"}}, {"GSM967862": {"TREATED WITH": "Bevacizumab (10mg/kg body weight)"}}], "ownerprofile_id": "arrayexpress_sid", "platform": 6, "summary_wrapped": "U87-EV human glioblastoma xenograft tumours is therapeutically treated by bevacizumab, a humanized anti-human VEGF mAb, or dibenzazepine...", "pubmed_id": 23871637, "geo_gse_id": "E-GEOD-39413", "owner_profile": "/profile/8773/arrayexpressuploader", "factor_count": 1, "sample_count": 14, "tags": ["point", "scid", "stroma"], "lastmodified": "Jun.29, 2015", "is_default": false, "geo_gds_id": "", "slug": "regulation-of-gene-expressions-in-vivo-by-anti-v-3", "geo_id_plat": "E-GEOD-39413_A-AFFY-45", "name": "Regulation of gene expressions in vivo by anti-VEGF and anti-Notch therapy [Mouse430_2]", "created": "Nov.12, 2014", "summary": "U87-EV human glioblastoma xenograft tumours is therapeutically treated by bevacizumab, a humanized anti-human VEGF mAb, or dibenzazepine (DBZ) when tumour is established in BALB/c SCID mice. At the end point, collect tumour samples and extracted total RNA for microarray to investigate the gene profile changes compared to control. These include the genes from human tumour cells and mouse host stroma cells. 5 control, 5 dibenzazepine-treated, and 4 bevacizumab-treated samples", "source": "http://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-39413", "species": "mouse", "sample_source": "http://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-39413/samples/"}